A metabolic reprogramming with involvement of Akt has previously also been reported in VR cells in other hematological cancers, and pharmacological inhibition of Akt has been shown to restore venetoclax sensitivity [24,25,26,28]. Here, AKT1 is linked to hematopoietic and lymphoid cell neoplasm.